Compare CarMax, Inc (KMX) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CarMax, Inc vs GeneDx Holdings Corp — how do they compare? CarMax, Inc trades at $58.32 (market cap $7.93B), while GeneDx Holdings Corp trades at $60.64 (market cap $1.80B). The key difference: CarMax, Inc is far larger — about 4.4× GeneDx Holdings Corp's market cap, and CarMax, Inc is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.
| KMX | WGS | |
|---|---|---|
Market Cap | $7.93B | $1.80B |
Sector | Consumer Cyclical | Technology |
52-Week High | $63.53 | $167.51 |
52-Week Low | $30.88 | $34.51 |
Enterprise Value | $26.44B | $1.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CarMax (KMX) trades at $55.89, down 2.51% on the day, with a bullish technical signal from moving averages but a neutral stance from oscillators. The company reported mixed earnings, with a Q2 2025 miss but subsequent beats in Q3 2025 and Q1 2026. Revenue has trended down from $31.9B in 2022 to $26.35B in 2025, though net income margin improved slightly to 1.89%. Recent news highlights a strategic turnaround under new CEO Keith Barr, with insider buying and positive analyst updates despite an ongoing legal investigation.
The outlook for KMX hinges on successful execution of its four-pillar strategy to boost volume and efficiency, offering potential upside if targets are met. However, high debt levels, margin pressure, and legal scrutiny pose significant risks. Analyst consensus is cautious with a hold-heavy rating and a price target of $48.91 below the current price, indicating skepticism about near-term growth.
GeneDx Holdings (WGS) trades at $60.65, down 4.46% amid a bearish technical signal and negative profitability. Recent earnings showed a Q1 2026 miss after two prior beats, with revenue growth but widening losses projected for 2026. The stock faces significant headwinds from multiple securities class action lawsuits alleging misrepresentations, with a deadline of August 3, 2026.
Despite a high analyst buy consensus (90.9%) and a $75.40 price target implying 24% upside, risks are elevated due to litigation, negative margins, and a high EV/EBITDA of 161.17. The upcoming Q2 2026 results on August 3 will be critical for investor confidence, but the legal overhang and fundamental challenges suggest cautious near-term outlook.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About CarMax, Inc
CarMax sells, finances, and services used and new cars through a chain of over 230 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales typically account for about 83% of revenue and wholesale about 13%, with the remaining portion composed of extended service plans and repair. In fiscal 2022, the company retailed and wholesaled 924,338 and 706,212 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the U.S. but still estimates that it has only about 4% U.S. market share of vehicles 0-10 years old in 2021. It seeks over 5% share by the end of calendar 2025 and revenue between $33 billion to $45 billion by fiscal 2026. CarMax is based in Richmond, Virginia.
Read more on KMX →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
